TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer

Herbst, Roy S., Prager, Diane, Hermann, Robert, Fehrenbacher, Lou, Johnson, Bruce E., Sandler, Alan, Kris, Mark G., Tran, Hai T., Klein, Pam, Li, Xin, Ramies, David, Johnson, David H., Miller, Vincent A.·2005·Journal of Clinical Oncology
DOI 10.1200/jco.2005.02.840

Cited by (1,000)

Items 501–600 of 1,000

  1. The roles of epidermal growth factor receptor (EGFR) inhibitors in the management of lung cancer
    Ashwaq Al Olayan, Hamad Al Hussaini, Abdul Rahman Jazieh · 2012 · Journal of Infection and Public Health
  2. Update on Taxanes in the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
    Mark A. Socinski · 2014 · Current Oncology
  3. First-line treatment for advanced non-small-cell lung cancer.
    Janessa J. Laskin, Alan B. Sandler · 2005 · PubMed
  4. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents
    Christophe Le Tourneau, Laura Vidal, Lillian L. Siu · 2008 · Drug Resistance Updates
  5. The Efficacy and Safety of EGFR Inhibitor Monotherapy in Non-Small Cell Lung Cancer: A Systematic Review
    Xiongwen Yang, Ke Yang, KangYu Kuang · 2014 · Current Oncology Reports
  6. Past, Present and Future of Targeted Therapy in Solid Tumors
    Antonella Palazzo, Roberto Iacovelli, Enrico Cortesi · 2010 · Current Cancer Drug Targets
  7. Hype or hope – Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?
    Filippo Papini, Janani Sundaresan, Alessandro Leonetti, Marcello Tiseo, Christian Diego Rolfo, Godefridus J. Peters, Elisa Giovannetti · 2021 · Critical Reviews in Oncology/Hematology
  8. Mind-mapping for lung cancer: Towards a personalized therapeutics approach
    Nathan M. Mollberg, Mosmi Surati, Carley Demchuk, Ramin Fathi, April K.S. Salama, Aliya Noor Husain, Thomas A. Hensing, Ravi Salgia · 2011 · Advances in Therapy
  9. Renal and Pulmonary Late Effects of Cancer Therapy
    Roderick Skinner, Rana Kaplan, Paul Craig Nathan · 2013 · Seminars in Oncology
  10. Ras and Ras mutations in cancer
    Satish Rajasekharan, Thiagarajan Raman · 2013 · Open Life Sciences
  11. Targeting the VEGF pathway: Antiangiogenic strategies in the treatment of non-small cell lung cancer
    Marianna Aita, Gianpiero Fasola, Carlotta Defferrari, Annalisa Brianti, Maria Giovanna Dal Bello, Alessandro Follador, Graziella Sinaccio, Paolo Pronzato, Francesco Grossi · 2008 · Critical Reviews in Oncology/Hematology
  12. Paclitaxel-Carboplatin Combination Chemotherapy in Advanced Breast Cancer: Accumulating Evidence for Synergy, Efficacy, and Safety
    George E. Pentheroudakis, Evangelia D. Razis, A. Athanassiadi, Nicholas A. Pavlidis, George Fountzilas · 2006 · Medical Oncology
  13. Recent advances in targeted therapy for non-small cell lung cancer
    Suresh S. Ramalingam, Chandra Prakash Belani · 2007 · Expert Opinion on Therapeutic Targets
  14. A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE)
    Karen E. Bullock, William P. Petros, Islam Rasem Younis, Hope Elizabeth Uronis, Michael Andrew Morse, Gerard C. Blobe, S. Yousuf Zafar, Jon P. Gockerman, Joanne J. Lager, Roxanne Williams-Truax et al. · 2010 · Cancer Chemotherapy and Pharmacology
  15. Intercalated Erlotinib-Docetaxel Dosing Schedules Designed to Achieve Pharmacodynamic Separation: Results of a Phase I/II Trial
    Randeep S. Sangha, Angela M. Davies, Primo N. Lara, Philip C. Mack, Laurel A. Beckett, Paul Joseph Hesketh, Derick H. Lau, Tianhong Li, Natasha Perkins, David R. Gandara · 2011 · Journal of Thoracic Oncology
  16. An International, Multicenter, Randomized Phase III Study of First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Versus First-Line Cisplatin/Gemcitabine Followed by Second-Line Erlotinib in Advanced Non–Small-Cell Lung Cancer: Treatment Rationale and Protocol Dynamics of the TORCH Trial
    Cesare Gridelli, Charles Andrew Butts, Fortunato Ciardiello, Ronald D. Feld, Ciro Gallo, Francesco Perrone · 2008 · Clinical Lung Cancer
  17. Targeted Therapy for Non–Small Cell Lung Cancer
    James R. Jett, Laurie L. Carr · 2013 · American Journal of Respiratory and Critical Care Medicine
  18. The Profile and Clinical Significance of ITGB2 Expression in Non-Small-Cell Lung Cancer
    Lingling Zu, Jinling He, Ning Zhou, Jingtong Zeng, Yifang Zhu, Quanying Tang, Xin Jin, Lei Zhang, Song Xu · 2022 · Journal of Clinical Medicine
  19. Gefitinib Monotherapy in Chemotherapy-Naive Patients with Inoperable Stage III/IV Non-Small-Cell Lung Cancer
    Martin Reck, Erika Buchholz, Kathrin Schott-von-Römer, Katrin Krützfeldt, Ulrich Gatzemeier, Christian Manegold · 2006 · Clinical Lung Cancer
  20. Investigation on the site-selective binding of bovine serum albumin by erlotinib hydrochloride
    Yan Liu, Mingmao Chen, Zhipu Luo, Jingjing Lin, Ling Song · 2012 · Journal of Biomolecular Structure and Dynamics
  21. Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib
    Hua Cheng, Shejuan An, Song Dong, Zhang Yi-fang, Xu‐Chao Zhang, Zhihong Chen, Jian-Su, Yi-Long Lung Cancer Wu · 2011 · Journal of Hematology & Oncology
  22. Maintenance Chemotherapy in Non–Small Cell Lung Cancer
    Keith D. Eaton, Renato G Martins · 2010 · Journal of the National Comprehensive Cancer Network
  23. Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non–Small-Cell Lung Cancer: SWOG S0536
    Edward S. Kim, James Moon, Roy S. Herbst, Mary Weber Redman, Shaker R. Dakhil, Mario R. Velasco, Fred R. Hirsch, Philip C. Mack, Karen L. Kelly, John Victor Heymach et al. · 2013 · Journal of Thoracic Oncology
  24. Radiation recall pneumonitis induced by erlotinib after palliative thoracic radiotherapy for lung cancer: Case report and literature review
    Raef Awad, Louise M. Nott · 2016 · Asia-Pacific Journal of Clinical Oncology
  25. Sulforaphene–Carboplatin Combination Synergistically Enhances Apoptosis by Disruption of Mitochondrial Membrane Potential and Cell Cycle Arrest in Human Non-Small Cell Lung Carcinoma
    Saswata Chatterjee, Yun‐Hee Rhee, Jin‐Chul Ahn · 2016 · Journal of Medicinal Food
  26. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Present and Future Role in Gastrointestinal Cancer Treatment: A Review
    Dirk Arnold, Stefan Peinert, Wieland Voigt, Hans‐Joachim Schmoll · 2006 · The Oncologist
  27. The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era.
    Zarnie Lwin, Jonathan Wesley Riess, David R. Gandara · 2013 · Europe PMC (PubMed Central)
  28. Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients?
    Antônio Rossi, Raffaella Pasquale, Claudia Esposito, Nicola Normanno · 2012 · Cancer Treatment Reviews
  29. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation–positive non-small cell lung cancers: an update for recent advances in therapeutics
    Clement Chung · 2015 · Journal of Oncology Pharmacy Practice
  30. First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009
    Ross Andrew Soo, Benjamin O. Anderson, Byoung Chul Cho, Chih-Hsin Yang, Meilin Liao, Wan‐Teck Lim, Peter G. Goldstraw, Tony S.K. Mok · 2009 · The Lancet Oncology
  31. Gemcitabine for the treatment of advanced nonsmall cell lung cancer
    Federico Cappuzzo · 2009 · OncoTargets and Therapy
  32. Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer: A systematic review
    Abdul Rahman Jazieh, Reem Al Sudairy, Nada Abu-Shraie, Wafaa Alsuwairi, Mazen Saleh Ferwana, MHassan Murad · 2013 · Annals of Thoracic Medicine
  33. Smoking History as a Predictive Factor of Treatment Response in Advanced Non–Small-Cell Lung Cancer: A Systematic Review
    Paul L R Mitchell, Tony S.K. Mok, Helen Barraclough, Alena Strizek, Rebecca A. Lew, Maximiliano Van Kooten · 2011 · Clinical Lung Cancer
  34. Experience with erlotinib in the treatment of non-small cell lung cancer
    Lorenza Maria Landi, Federico Cappuzzo · 2015 · Therapeutic Advances in Respiratory Disease
  35. Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance
    Giulio Metro, Giovanna Finocchiaro, Federico Cappuzzo · 2006 · Annals of Oncology
  36. Management of Rash and Other Toxicities in Patients Treated with Epidermal Growth Factor Receptor—Targeted Agents
    Jay Rhee, Karen Oishi, Jody S. Garey, Edward Jae-Hoon Kim · 2005 · Clinical Colorectal Cancer
  37. Principles of Dose, Schedule, and Combination Therapy
    William N. Hait, Joseph P. Eder · 2019 · Wiley eBooks
  38. Cost-Effectiveness of Maintenance Pemetrexed in Patients with Advanced Nonsquamous-Cell Lung Cancer from the Perspective of the Swiss Health Care System
    Klazien W Matter-Walstra, Markus Joerger, Ursula Kühnel, Thomas D. Szucs, Bernhard C. Pestalozzi, Matthias M. Schwenkglenks · 2011 · Value in Health
  39. Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity
    Nelson Ung, Tracy L. Putoczki, Stanley S. Stylli, Irvin Ng, John M. Mariadason, Timothy An-thy Chan, Hong‐Jian Zhu, Rodney Brian Luwor · 2014 · Cancer Biology & Therapy
  40. Quantitative Immunohistochemistry for Evaluating the Distribution of Ki67 and Other Biomarkers in Tumor Sections and Use of the Method to Study Repopulation in Xenografts after Treatment with Paclitaxel
    Andrea S. Fung, James E. N. Jonkman, Ian F. Tannock · 2012 · Neoplasia
  41. Epidermal Growth Factor Receptor Inhibitors and Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer
    Leora Horn, Alan B. Sandler · 2009 · Clinical Cancer Research
  42. Elevated International Normalized Ratio associated with concomitant warfarin and erlotinib
    Kelly Thomas, Amanda Billingsley, Naseem Amarshi, Balagopalan A. Nair · 2010 · American Journal of Health-System Pharmacy
  43. Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications
    Ludmila Prudkin, Ignacio Ivan Wistuba · 2006 · Annals of Diagnostic Pathology
  44. Therapeutic Strategy for Treatment of Metastatic Non-Small Cell Lung Cancer
    Malik Berhoune, Eugéniu Banu, Florian Scotté, P. Prognon, Stéphane Marie. Oudard, Brigitte Bonan · 2008 · Annals of Pharmacotherapy
  45. Setting the Benchmark For Tailoring Treatment With Egfr Tyrosine Kinase Inhibitors
    Rafael Rosell, Miquel Tarón, José Javier Sánchez, Luis G Paz-Ares · 2007 · Future Oncology
  46. Phase II Trial of Bexarotene Capsules in Patients With Advanced Non–Small-Cell Lung Cancer After Failure of Two or More Previous Therapies
    Ramaswamy Govindan, John J. Crowley, Lee Steven Schwartzberg, Peter Kennedy, Charles C. Williams, Bradley C. Ekstrand, Alan B. Sandler, D. Jaunakais, Vanessa Bolejack, Richard Ghalie · 2006 · Journal of Clinical Oncology
  47. Strategies for improving outcomes in NSCLC: A look to the future
    Rolf Arno Stahel, Solange Peters, Paul Baas, Elisabeth M. Brambilla, Federico Cappuzzo, Dirk De Ruysscher, Wilfried Eberhardt, Enriqueta Felip, Dean Anthony Fennell, Antonio Marchetti et al. · 2013 · Lung Cancer
  48. Methodological aspects of lung cancer clinical trials in the era of targeted agents
    Massimo Di Maïo, Ciro Gallo, Ermelinda De Maio, Alessandro Morabito, Maria Carmela Piccirillo, Cesare Gridelli, Francesco Perrone · 2009 · Lung Cancer
  49. Cetuximab in combination therapy: from bench to clinic
    David E. Gerber, Hak Choy · 2010 · Cancer and Metastasis Reviews
  50. Recent Advances in Personalized Lung Cancer Medicine
    Ross A. Okimoto, Trever Grant Bivona · 2014 · Personalized Medicine
  51. A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours
    Aneta Suder, J.E. Ang, Fiona J. Kyle, D. Harris, Sarah Maria Rudman, Rebecca Sophie Kristeleit, Flavio Solca, Martina Uttenreuther‐Fischer, Karine Pemberton, Katy Pelling et al. · 2015 · European Journal of Cancer
  52. Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy
    Yuh‐Min Chen, Jacqueline Ming Liu, Teh‐Ying Chou, Reury-Perng Perng, Chun‐Ming Tsai, Jacqueline Whang‐Peng · 2007 · Cancer
  53. Schedule-Dependent Interaction between the Proteosome Inhibitor Bortezomib and the EGFR-TK Inhibitor Erlotinib in Human Non-small Cell Lung Cancer Cell Lines
    Bilal Piperdi, Yi‐He Ling, Roman Perez-Soler · 2007 · Journal of Thoracic Oncology
  54. Subsequent Chemotherapy Improves Survival Outcome in Advanced Non–Small-Cell Lung Cancer With Acquired Tyrosine Kinase Inhibitor Resistance
    Chih-Hsi Scott Kuo, Shu‐Min Lin, Kang-Yun Lee, Fu‐Tsai Chung, Meng‐Heng Hsieh, Yueh‐Fu Fang, Chih‐Ten Yu, Han-Pin Kuo · 2010 · Clinical Lung Cancer
  55. Role of erlotinib in the management of pancreatic cancer
    N. Starling, J. Neoptolemos, D. Cunningham · 2006 · Therapeutics and Clinical Risk Management
  56. Prognostic implications of hypoxia-inducible factor-1α in epidermal growth factor receptor-negative non-small cell lung cancer
    Sanghui Park, Seung Yeon Ha, Hyun Yee Cho, Dong Hae Chung, Na Rae Kim, Junshik Hong, Eun Kyung Cho · 2010 · Lung Cancer
  57. Chemotherapy plus Erlotinib versus Chemotherapy Alone for Treating Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
    Jianlin Xu, Bo Jin, Zhen‐Hu Ren, Yuqing Lou, Zirou Zhou, Qiuxia Yang, Baohui Han · 2015 · PLoS ONE
  58. Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib and Erlotinib in the Treatment of Non-small Cell Lung Cancer: A Systematic Review
    Ron Feld, Srikala S. Sridhar, Frances A. Shepherd, Jean A. Mackay, William Kenneth Evans · 2006 · Journal of Thoracic Oncology
  59. Chronopharmacology and Mechanism of Antitumor Effect of Erlotinib in Lewis Tumor-Bearing Mice
    Peipei Wang, Fengmei An, Xingjun Zhuang, Jiao Liu, Liyan Zhao, Bin Zhang, Liang Liu, Pingping Lin, Mingchun Li · 2014 · PLoS ONE
  60. A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer
    Hui Yu, Jian Zhang, Xianghua Wu, Zhiguo Luo, Huijie Wang, Si Sun, Wei Jun Peng, Jie Qiao, Yu Feng, Jialei Wang et al. · 2014 · Cancer Biology & Therapy
  61. Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis.
    Yuxia Jia, Mario E. Lacouture, Xiao Qun Su, Shenhong Wu · 2009 · PubMed
  62. Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors
    Chia‐Chi Lin, Hsin-Hsin Hsu, Chia‐Tung Shun, Jin‐Yuan Shih, Zhong‐Zhe Lin, Chong‐Jen Yu, George G. Chen, Michael Kuan Yew Hsin, Kwok Chi Lam, Linda K. S. Leung et al. · 2010 · Journal of Thoracic Oncology
  63. What is the Best Strategy for Targeting EGF Receptors in Non-Small-Cell Lung Cancer?
    Robert Pirker · 2015 · Future Oncology
  64. Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials
    Angela M. DeMichele, Donald A. Berry, Jo Anne Zujewski, Sally Hunsberger, Larry Rubinstein, Joseph E. Tomaszewski, Kelloff Gj, Jane Perlmutter, Meredith Buxton, Julia Lyandres et al. · 2013 · Clinical Cancer Research
  65. Retrospective Practice Review of Treatment of Metastatic Non-Small-Cell Lung Cancer with Second-Line Erlotinib
    B. Melosky, Jason Scott Agulnik, Hazem I. Assi · 2008 · Current Oncology
  66. Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists
    Kim Tam Bui, Wendy A. Cooper, Steven Kao, Michael Joseph Boyer · 2018 · Journal of Clinical Medicine
  67. Small-molecule inhibitors of the human epidermal receptor family
    Corey Allan Carter, Ronan Joseph Kelly, Giuseppe Giaccone · 2009 · Expert Opinion on Investigational Drugs
  68. Cutaneous Reactions Related to Systemic Immunomodulators and Targeted Therapeutics
    Lisa A. Hammond-Thelin · 2007 · Dermatologic Clinics
  69. Current Approaches to Advanced-Stage Non–Small-Cell Lung Cancer: First-Line Therapy in Patients with a Good Functional Status
    Thomas E. Stinchcombe, Carrie B. Lee, Mark A. Socinski · 2006 · Clinical Lung Cancer
  70. Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer
    Eckart Laack, Guido Sauter, Carsten Bokemeyer · 2010 · Lung Cancer
  71. A Phase II Randomized Trial of Gefitinib Alone or with Tegafur/Uracil Treatment in Patients with Pulmonary Adenocarcinoma Who had Failed Previous Chemotherapy
    Yuh-Min Chen, Wen-Chien Fan, Chun‐Ming Tsai, Shih-Hao Liu, Jen-Fu Shih, Teh‐Ying Chou, Chieh-Hung Wu, Kun‐Ta Chou, Yu-Chin Lee, Reury-Perng Perng et al. · 2011 · Journal of Thoracic Oncology
  72. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer
    Elena Galvani, Roberta R Alfieri, Elisa Giovannetti, Andrea Cavazzoni, Silvia La Monica, Maricla Galetti, Claudia Fumarola, Mara A. Bonelli, Marco Mor, Marcello Tiseo et al. · 2012 · Current Pharmaceutical Design
  73. A Phase I Clinical and Pharmacokinetic Study of Oral CI-1033 in Combination with Docetaxel in Patients with Advanced Solid Tumors
    Linda L. Garland, Manuel M. Hidalgo, David S. Mendelson, David P. Ryan, Banu K Arun, Jennifer L. Lovalvo, Irene A. Eiseman, Stephen C. Olson, Peter F. Lenehan, Joseph P. Eder · 2006 · Clinical Cancer Research
  74. Efectos cutáneos de los inhibidores del receptor del factor de crecimiento epidérmico
    G. Guhl, A. González-de Arriba, Esteban Daudén · 2006 · Actas Dermo-Sifiliográficas
  75. Acute drug induced hepatitis due to erlotinib.
    Jeyanthi Ramanarayanan, Sarah L Scarpace · 2007 · PubMed
  76. First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?
    Shuyun Wang, Aiqin Gao, Jie Liu, Yuping Sun · 2018 · Cancer Chemotherapy and Pharmacology
  77. The Role of Pharmacoethnicity in the Development of Cytotoxic and Molecular Targeted Drugs in Oncology
    Nagahiro Saijo · 2012 · Yonsei Medical Journal
  78. Targeted Therapy for Solid Tumors: Current Status
    Amer H. Zureikat, Mark D. McKee · 2008 · Surgical Oncology Clinics of North America
  79. Third CECOG consensus on the systemic treatment of non-small-cell lung cancer
    Thomas Brodowicz, Tudor–Eliade Ciuleanu, Jeffrey Crawford, Martin Filipits, Jürgen R. Fischer, Vassilis Georgoulias, Cesare Gridelli, Fred R. Hirsch, Jacek Jassem, P. Kosmidis et al. · 2011 · Annals of Oncology
  80. Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung
    Glenwood D. Goss, Johanna N. Spaans · 2016 · The Oncologist
  81. Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial
    Zsolt Markóczy, Veronika Sárosi, Iveta Kudaba, Gabriella Gálffy, Ülkü Yılmaz Turay, Ahmet Demirkazık, Gunta Purkalne, Attila Somfay, Zsolt Pápai-Székely, Erzsébet Rásó et al. · 2018 · BMC Cancer
  82. A randomized, double-blind, placebo-controlled study of B-cell lymphoma 2 homology 3 mimetic gossypol combined with docetaxel and cisplatin for advanced non-small cell lung cancer with high expression of apurinic/apyrimidinic endonuclease 1
    Yuxiao Wang, Xuemei Li, Liang Zhang, Mengxia Li, Nan Dai, Hao Luo, Jinlu Shan, Xueqin Yang, Mingfang Xu, Yan Feng et al. · 2020 · Investigational New Drugs
  83. Maintenance therapy in nonsmall‐cell lung cancer
    Tony S.K. Mok, Suresh S. Ramalingam · 2009 · Cancer
  84. Phase 2 trial of docetaxel and gefitinib in the first‐line treatment of patients with advanced nonsmall‐cell lung cancer (NSCLC) who are 70 years of age or older
    George R. Simon, Martine Extermann, Alberto Chiappori, Charles C. Williams, Mubeena Begum, Rachna Kapoor, Eric B. Haura, Roohi R. Ismail-Khan, Michael J. Schell, Scott Joseph Antonia et al. · 2008 · Cancer
  85. Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer
    Alice De Sanctis, Laurent Taillade, Stéphane Vignot, Silvia Novello, Rosa Conforti, Jean‐Philippe Spano, Giorgio V. Scagliotti, David Khayat · 2011 · Cancer
  86. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor
    Daniel J. Freeman, Tammy L. Bush, Selam Ogbagabriel, Brian Belmontes, Todd Juan, Cherylene A. Plewa, Gwyneth Y. Van, Carol Johnson, Robert Radinsky · 2009 · Molecular Cancer Therapeutics
  87. Long acting somatostatin analogues in combination to antineoplastic agents in the treatment of small cell lung cancer patients
    Paul Zarogoulidis, Ellada Eleftheriadou, Theodoros Kontakiotis, George Gerasimou, Paul Zarogoulidis, I. Sapardanis, Grammati Galaktidou, Leonidas Sakkas, Anna Gotzamani‐Psarrakou, Nikolaos D. Karatzas · 2011 · Lung Cancer
  88. Erlotinib
    Martin B. Steins, Michael Thomas, Michael Geißler · 2018 · Recent results in cancer research/Recent Results in Cancer Research
  89. Trying to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer
    Massimo Di Maïo, Cesare Gridelli, Nicola Normanno, Federica Perrone, Fortunato Ciardiello · 2005 · Journal of Cellular Physiology
  90. Targeted therapy in advanced non-small cell lung cancer (NSCLC): Where do we stand?
    Hatem A. Azim, Apar Kishor Ganti · 2006 · Cancer Treatment Reviews
  91. Cytotoxic activity of paclitaxel incorporated into polyelectrolyte nanocapsules
    Alicja Karabasz, Monika Bzowska, Sylwia Łukasiewicz, Joanna Bereta, Krzysztof Szczepanowicz · 2014 · Journal of Nanoparticle Research
  92. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer
    Kazuhiro Asami · 2014 · World Journal of Clinical Oncology
  93. Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations
    Matjaž Zwitter, Mirjana Rajer, Karmen Stanič, Martina Vrankar, Andrej Doma, Anka Cuderman, Marko Grmek, Izidor Kern, Viljem Kovač · 2016 · Cancer Biology & Therapy
  94. Targeted Therapy for Non-Small Cell Lung Cancer
    Zorawar Singh Noor, Amy Lauren Cummings, McKenna M. Johnson, Marshall L. Spiegel, Jonathan Wade Goldman · 2020 · Seminars in Respiratory and Critical Care Medicine
  95. High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy
    Reury-Perng Perng, Chih-Hsin Yang, Yuh-Min Chen, Gee‐Chen Chang, Meng‐Chih Lin, Ruey‐Kuen Hsieh, Nei‐Min Chu, Ruay-Sheng Lai, Wu‐Chou Su, Chao-Jung Tsao et al. · 2008 · Lung Cancer
  96. Cisplatin treatment induced interleukin 6 and 8 production alters lung adenocarcinoma cell migration in an oncogenic mutation dependent manner
    Edit Kiss, Elhusseiny Mohamed Mahmoud Abdelwahab, Anita Steib, Emőke Papp, Zsofia Torok, Laszlo Jakab, Gábor Smuk, Veronika Sárosi, Judit Erzsebet Pongracz · 2020 · Respiratory Research
  97. Phase I Pharmacokinetic/Pharmacodynamic Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Combination with Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in First-Line Treatment of Patients with Metastatic Colorectal Cancer
    Gunnar Folprecht, Josep M. Tabernero, Claus‐Henning Köhne, Charles Zacharchuk, Luis G Paz-Ares, Federico Rojo, Susan Quinn, Esther Casado, Ramón Salazar, Richat Abbas et al. · 2008 · Clinical Cancer Research
  98. Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors
    Amita Patnaik, Debra L. Wood, Anthony W. Tolcher, Marta Hamilton, Jeffrey I. Kreisberg, Lisa A. Hammond, Garry H. Schwartz, Muralidhar Beeram, Manuel M. Hidalgo, Monica M Mita et al. · 2006 · Clinical Cancer Research
  99. Targeting HER1/EGFR in Cancer Therapy: Experience with Erlotinib
    Giuseppe Giaccone · 2005 · Future Oncology
  100. Epidermal Growth Factor Receptor Inhibitors plus Chemotherapy in Non–Small-Cell Lung Cancer: Biologic Rationale for Combination Strategies
    David R. Gandara, Angela M. Davies, Oliver Pascal Gautschi, Philip C. Mack, Derick H. Lau, Primo N. Lara, Fred R. Hirsch · 2007 · Clinical Lung Cancer